A Phase II, Randomized, Double-blind, Active-controlled, Dose-escalation Study to Determine the Maximum Well-tolerated Dose of Ropinirole Controlled-release (CR) in Parkinson's Disease Patients Not Receiving Other Dopaminergic Therapies

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/009/1/02

Funding

  • Parexel International Co: $9,530.00